Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Nov 15;145(10):2682-2691.
doi: 10.1002/ijc.32304. Epub 2019 Apr 15.

Opportunistic testing of BRCA1, BRCA2 and mismatch repair genes improves the yield of phenotype driven hereditary cancer gene panels

Lídia Feliubadaló  1   2   3 , Adrià López-Fernández  4 , Marta Pineda  1   2   3 , Orland Díez  5   6 , Jesús Del Valle  1   2   3 , Sara Gutiérrez-Enríquez  5 , Alex Teulé  1   2   3 , Sara González  1   2   3 , Neda Stjepanovic  4   7 , Mónica Salinas  1   2   3 , Gabriel Capellá  1   2   3 , Joan Brunet  1   8   9 , Conxi Lázaro  1   2   3 , Judith Balmaña  4   7 ; Catalan Hereditary Cancer Group
Collaborators, Affiliations

Opportunistic testing of BRCA1, BRCA2 and mismatch repair genes improves the yield of phenotype driven hereditary cancer gene panels

Lídia Feliubadaló et al. Int J Cancer. .

Abstract

Multigene panels provide a powerful tool for analyzing several genes simultaneously. We evaluated the frequency of pathogenic variants (PV) in customized predefined panels according to clinical suspicion by phenotype and compared it to the yield obtained in the analysis of our clinical research gene panel. We also investigated mutational yield of opportunistic testing of BRCA1/2 and mismatch repair (MMR) genes in all patients. A total of 1,205 unrelated probands with clinical suspicion of hereditary cancer were screened for germline mutations using panel testing. Overall, 1,048 females and 157 males were analyzed, mean age at cancer diagnosis was 48; 883 had hereditary breast/ovarian cancer-suspicion, 205 hereditary nonpolyposis colorectal cancer (HNPCC)-suspicion, 73 adenomatous-polyposis-suspicion and 44 with other/multiple clinical criteria. At least one PV was found in 150 probands (12%) analyzed by our customized phenotype-driven panel. Tumoral MMR deficiency predicted for the presence of germline MMR gene mutations in patients with HNPCC-suspicion (46/136 vs. 0/56 in patients with and without MMR deficiency, respectively). Opportunistic testing additionally identified five MSH6, one BRCA1 and one BRCA2 carriers (0.6%). The analysis of the extended 24-gene panel provided 25 additional PVs (2%), including in 4 out of 51 individuals harboring MMR-proficient colorectal tumors (2 CHEK2 and 2 ATM). Phenotype-based panels provide a notable rate of PVs with clinical actionability. Opportunistic testing of MMR and BRCA genes leads to a significant straightforward identification of MSH6, BRCA1 and BRCA2 mutation carriers, and endorses the model of opportunistic testing of genes with clinical utility within a standard genetic counseling framework.

Keywords: actionability; cancer susceptibility; germline cancer panel.

PubMed Disclaimer

References

    1. Shah PD, Nathanson KL. Application of panel-based tests for inherited risk of cancer. Annu Rev Genomics Hum Genet 2017;18:201-27.
    1. Desmond A, Kurian AW, Gabree M, et al. Clinical actionability of multigene panel testing for hereditary breast and ovarian cancer risk assessment. JAMA Oncol 2015;1:943-51.
    1. Tung N, Domchek SM, Stadler Z, et al. Counselling framework for moderate-penetrance cancer-susceptibility mutations. Nat Rev Clin Oncol 2016;13:581-8.
    1. Easton DF, Pharoah PDP, Antoniou AC, et al. Special report gene-panel sequencing and the prediction of breast-cancer risk. N Engl J Med 2015;372:2243-57.
    1. Couch FJ, Shimelis H, Hu C, et al. Associations between cancer predisposition testing panel genes and breast cancer. JAMA Oncol 2017;3:1190-6.

Publication types